Clinical Trial Update: Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating allogeneic NK cell adoptive transfer in combination with cetuximab for metastatic gastrointestinal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer

Drugs mentioned

• Allogeneic natural killer (NK) cell therapy (allogeneic NK cell therapy)
• ERBITUX (cetuximab)

Snippet

Sponsor: Centre Hospitalier Universitaire de Besancon | Conditions: Gastrointestinal Metastatic Cancer | Phase 1 | Status: COMPLETED